MannKind Posts 15% Revenue Growth, Eyes Pediatric Afrezza Approval
Event summary
- Q1 2026 revenues rose 15% YoY to $90.2M, driven by Furoscix and royalty growth.
- Furoscix sales hit $15.5M with 64% dose growth YoY; Afrezza sales at $15.3M.
- Pediatric Afrezza PDUFA date set for May 29, 2026; Furoscix Autoinjector PDUFA on July 26, 2026.
- United Therapeutics added $5M to ralinepag DPI collaboration, with $35M in potential milestones.
- Cash position at $134M after settling $36.3M in convertible notes.
The big picture
MannKind is pivoting toward a diversified portfolio of cardiometabolic and orphan lung disease therapies, with 2026 shaping up as a pivotal year for regulatory approvals. The company's strategic shift toward dry powder inhalers (DPIs) aligns with industry trends favoring patient-centric, convenient drug delivery. Success hinges on executing launches and sustaining pipeline momentum amid rising costs.
What we're watching
- Regulatory Catalysts
- Whether Afrezza's pediatric approval and Furoscix Autoinjector clearance will expand market access and drive revenue growth.
- Pipeline Momentum
- The pace at which nintedanib DPI (MNKD-201) advances into Phase 2 and ralinepag DPI (MNKD-1501) progresses under United Therapeutics.
- Financial Discipline
- How MannKind balances investment in commercial expansion against rising operating expenses and debt obligations.